Takuya Moriya

Prof. Takuya Moriya

Kawasaki Medical School, Kurashiki, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
YTYoshifumi Takahashi
Yoshifumi Takahashi
TKTakahiro Koyanagi
Takahiro Koyanagi
YSYasuhiro Suzuki
Yasuhiro Suzuki
YSYasushi Saga
Yasushi Saga
NKNaoki Kanomata
Naoki Kanomata
YSYasufumi Sato
Yasufumi Sato
Vasohibin-1 (VASH1) is a VEGF-inducible endothelium-derived angiogenesis inhibitor and VASH2 is its homolog. Our previous analysis revealed that VASH1 is expressed in endothelial cells to terminate angiogenesis, whereas VASH2 is expressed in infiltrating mononuclear cells mobilized from bone marrow to promote angiogenesis in a mouse model of hypoxia-induced subcutaneous angiogenesis. To test the possible involvement of VASH2 in the tumor, we examined human ovarian cancer cells for the presence of VASH2. Immunohistochemical analysis revealed that VASH2 protein was preferentially detected in cancer cells of serous ovarian adenocarcinoma. We then used SKOV-3 and DISS, two representative human serous adenocarcinoma cell lines, and examined the role of VASH2 in the tumor. The knockdown of VASH2 showed little effect on the proliferation of cancer cells in vitro but notably inhibited tumor growth, peritoneal dissemination, and tumor angiogenesis in a murine xenograft model. Next, we stably transfected the human VASH2 gene into two types of murine tumor cells, EL-4 and MLTC-1, in which endogenous VASH2 was absent. When either EL-4 or MLTC-1 cells were inoculated into VASH2 (−/−) mice, the VASH2 transfectants formed bigger tumors when compared with the controls, and the tumor microvessel density was significantly increased. VASH2 stimulated the migration of endothelial cells, and its increased expression in cancer cells is related to the decrease of mir-200b. These results indicate that VASH2 expressed in serous ovarian carcinoma cells promoted tumor growth and peritoneal dissemination by promoting angiogenesis. Mol Cancer Res; 10(9); 1135–46. ©2012 AACR.

1 January 2009 in Pathology
Verified
Journal Article
Closed access
PDF file
TMTakuya Moriya
Takuya Moriya
YKYuji Kozuka
Yuji Kozuka
NKNaoki Kanomata
Naoki Kanomata
GTGary M. Tse
Gary M. Tse
PTPuay-Hoon Tan
Puay-Hoon Tan
Immunohistochemistry may be helpful in the diagnosis of various breast lesions. It can be used to assist in distinguishing benign and malignant conditions, or to clarify the histological subtype of invasive carcinomas. There are several markers relatively frequently utilised. Myoepithelial markers (p63, alpha-SMA, smooth muscle myosin heavy chain, and others) are useful to highlight myoepithelial cells. They are employed to verify myoepithelial cell lining in intraductal papillary lesions, or to recognise peripheral myoepithelial cells for non-invasive carcinoma, although their staining results are not always excellent. High molecular weight cytokeratins (CK5/6, CK14, 34βE12) typically show a mosaic-like pattern of expression in benign papillary/hyperplastic lesions, and are mostly negative in ductal in situ carcinoma, but some exceptions exist. Neuroendocrine differentiation (confirmed by anti-chromogranin A or synaptophysin) suggests malignancy in solid and papillary intraductal epithelial proliferations. The significance of immunohistochemical evaluation of apocrine lesions is still controversial.Negative E-cadherin staining is used for making confirmative diagnosis of lobular carcinoma, with a specificity and sensitivity of approximately 90%. Cytokeratins, especially the antibody 34βE12, are of value to differentiate spindle cell carcinoma from phyllodes tumour. There are some other useful markers for characterising certain histological subtypes.Nevertheless, for accurate diagnosis, it is essential to correlate the immmunohistochemical staining results with the histological findings

20 October 2010 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JKJunichi Kurebayashi
Junichi Kurebayashi
NKNaoki Kanomata
Naoki Kanomata
TMTakuya Moriya
Takuya Moriya
YKYuji Kozuka
Yuji Kozuka
MWMika Watanabe
Mika Watanabe
HSHiroshi Sonoo
Hiroshi Sonoo
Recent studies have suggested that the Src inhibitor dasatinib preferentially inhibits the growth of breast cancer cells of the basal-like subtype. To clarify this finding and further investigate combined antitumor effects of dasatinib with cytotoxic agents, a panel of breast cancer cell lines of various subtypes was treated with dasatinib and/or chemotherapeutic agents.

1 October 2007 in Breast Cancer
Verified
Journal Article
Closed access
PDF file
MIMasahiro Ito
Masahiro Ito
TMTakuya Moriya
Takuya Moriya
TITakanori Ishida
Takanori Ishida
SUShin Usami
Shin Usami
AKAtsuko Kasajima
Atsuko Kasajima
NONoriaki Ohuchi
Noriaki Ohuchi
Background Lymphatic vessel invasion (LVI) has been conventionally assessed on hematoxylineosin (HE) stained sections, but this assessment tends to be subjective. The aim of this study is to...

1 January 2001 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
TSTakashi Suzuki
Takashi Suzuki
TMTakuya Moriya
Takuya Moriya
Akira SugawaraAkira Sugawara
Akira Sugawara
NANaohira Ariga
Naohira Ariga
HTHiroaki Takabayashi
Hiroaki Takabayashi
HSHironobu Sasano
Hironobu Sasano

1 May 2001 in Pathology International
Verified
Journal Article
Closed access
PDF file
SMSuzuko Moritani
Suzuko Moritani
TMTakuya Moriya
Takuya Moriya
RKRyoji Kushima
Ryoji Kushima
HSHiroyuki Sugihara
Hiroyuki Sugihara
MHMinoru Harada
Minoru Harada
THTakanori Hattori
Takanori Hattori